The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway.

Brain Research
L A AndersonJ R Walters

Abstract

The effect of cannabinoid receptor stimulation on rotational behavior induced by a dopamine D1 and a D2 agonist was studied in rats with unilateral 6-hydroxydopamine-induced lesions of the dopaminergic nigrostriatal pathway. The cannabinoid agonists WIN 55,212-2 (2.5 mg/kg) and CP 55,940 (0.1 mg/kg) both markedly attenuated contralateral rotation induced by the D1 agonist SKF 38393 (1.5 mg/kg). In contrast, WIN 55,212-2 and CP 55,940 did not alter rotation elicited by the D2 agonist quinpirole (0.1 mg/kg). Doses of WIN 55,212-2 and CP 55,940 that attenuated D1-mediated rotation did not produce catalepsy in intact rats or in rats with 6-hydroxydopamine-induced lesions, indicating that the reduction in rotation produced by the cannabinoids was not due to a generalized motor impairment. In addition, the effective dose of WIN 55,212-2, but not CP 55,940, produced only a slight increase in ipsilateral rotation when administered alone, making it improbable that this ipsilateral tendency accounts for the reduction in D1-mediated contralateral rotation. These results suggest a preferential interaction between cannabinoid receptor stimulation and dopamine D1 receptor-mediated behavior.

References

Dec 7, 1978·Nature·J L Waddington, A J Cross
Jan 11, 1979·Nature·J W Kebabian, D B Calne
Feb 11, 1992·Trends in Pharmacological Sciences·D R Sibley, F J Monsma
Nov 1, 1991·Journal of Neurochemistry·M Bidaut-Russell, A C Howlett
Feb 1, 1992·Journal of Neurochemistry·D M EvansA C Howlett
May 3, 1991·Brain Research·M HerkenhamE K Richfield
Oct 1, 1990·Brain Research·M B HarrisonG F Wooten
Jul 1, 1990·Journal of Neurochemistry·M Bidaut-RussellA C Howlett
Jan 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·C Le MoineB Bloch
Oct 1, 1989·Trends in Neurosciences·R L AlbinJ B Penney
Nov 1, 1986·The International Journal of Neuroscience·P ConsroeS R Snider
Aug 1, 1981·Journal of Clinical Pharmacology·D J Petro, C Ellenberger
Nov 1, 1981·Pharmacology, Biochemistry, and Behavior·D E MossJ Rogers
Jun 1, 1983·Annals of Neurology·D B Clifford
Aug 1, 1993·Trends in Neurosciences·D J SurmeierM A Ariano
Feb 9, 1993·European Journal of Pharmacology·E Fride, R Mechoulam
Jan 1, 1993·Journal of Psychopharmacology·M Hemming, P M Yellowlees

❮ Previous
Next ❯

Citations

May 23, 1996·European Journal of Pharmacology·A S Miller, J M Walker
Mar 7, 1998·European Journal of Pharmacology·G L GessaM Diana
Aug 17, 2002·Pharmacology & Therapeutics·Julián RomeroJavier Fernández-Ruiz
Feb 1, 1997·The European Journal of Neuroscience·M GlassY P Maneuf
Jan 8, 1999·Acta Psychiatrica Scandinavica·K R Müller-VahlH M Emrich
Sep 14, 2006·Pharmacological Reviews·Pál PacherGeorge Kunos
Jan 26, 2007·Journal of Neurochemistry·David A PriceAndrea Giuffrida
Apr 19, 2015·Molecular Neurodegeneration·Sandeep Vasant More, Dong-Kug Choi
Jan 23, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Gregorio SegoviaJonathan M Brotchie
Mar 23, 2017·Reviews in the Neurosciences·Hossein Sanjari MoghaddamNima Rezaei
Jan 5, 2017·Parkinson's Disease·Mariana BabayevaZvi Loewy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.